1 Goldberg SL,Chen E,Corral M,et al.Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries[J].J Clin Oncol,2010,28(17):2847-2852. 2 Gattermann N,Finelli C,Della PM,et al.Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes[J].Haematologica,2012,97(9):1364-1371. 3 黄蕾,付蓉,邵宗鸿.铁过载组织损伤特点及机制研究进展[J].中华血液学杂志,2012,33(10):884-887. 4 Chiabrando D,Vinchi F,Fiorito V,et al.Heme in pathophysiology:a matter of scavenging,metabolism and trafficking across cell membranes[J].Front Pharmacol,2014,5(5):61. 5 Lawen A,Lane DJ.Mammalian iron homeostasis in health and disease:uptake,storage,transport,and molecular mechanisms of action[J].Antioxid Redox Signal,2013,18(18):2473-2507. 6 Brissot P,Deugnier Y,Guyader D,et al.Iron overload and the biliary route[J].Advances in Experimental Medicine & Biology,1994,356(356):277-283. 7 Hellstr-Lindberg E.Management of anemia associated with myelodysplastic syndrome[J].Seminars in Hematology,2005,42(2 Suppl 1):10-13. 8 Jomova K,Valko M.Advances in metal-induced oxidative stress and human disease[J].Toxicology,2011,283(2/3):65-87. 9 Zuo Y,Xiang B,Yang J,et al.Oxidative modification of caspase-9 facilitates its activation via disulfide-mediated interaction with Apaf-1[J].Cell Res,2009,19(4):449-457. 10 Telfer P.Update on survival in thalassemia major[J].Hemoglobin,2009,33(Suppl1):76-80. 11 Yang JC,Robert C,Gough SM,et al.Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome[J].Leuk Res,2014,38(1):95-102. 12 Bejar R,Stevenson K,Abdelwahab O,et al.Clinical effect of point mutations in myelodysplastic syndromes[J].N Engl J Med,2011,364(26):2496-2506. 13 Pullarkat V.Objectives of iron chelation therapy in myelodysplastic syndromes:more than meets the eye?[J].Blood,2009,114(26):5251-5255. 14 Kikuchi S,Kobune M,Iyama S,et al.Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox[J].Free Radic Biol Med,2012,53(4):643-648. 15 Badawi MA,Vickars LM,Chase JM,et al.Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome[J].Adv Hematol,2010,2010:1687-9104. 16 List AF,Baer MR,Steensma DP,et al.Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome[J].J Clin Oncol,2012,30(17):2134-2139. 17 Baldomero H,Gratwohl M,Gratwohl A,et al.The EBMT activity survey 2009:trends over the past 5 years[J].Bone Marrow Transplantation,2011,46(4):485-501. 18 Gaziev J,Sodani P,Polchi P,et al.Bone marrow transplantation in adults with thalassemia:treatment and long-term follow-up[J].Ann N Y Acad Sci,2005,1054(1):196-205. 19 Kanda J,Mizumoto C,Ichinohe T,et al.Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation[J].Bone Marrow Transplantation,2011,46(2):208-216. 20 Armand P,Kim HT,Rhodes J,et al.Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation[J].Biol Blood Marrow Transplant,2011,17(6):852-860. 21 Wermke M,Schmidt A,Middeke JM,et al.MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation[J].Clin Cancer Res,2012,18(23):6460-6468. 22 Maradei S C,Maiolino A,de Azevedo A M,et al.Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation[J].Blood,2009,114(6):1270-1275. 23 Pullarkat V,Blanchard S,Tegtmeier B,et al.Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation[J].Bone Marrow Transplantation,2008,42(12):799-805. 24 Tachibana T,Tanaka M,Takasaki H,et al.Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies[J].Int J Hematol,2011,93(3):368-374. 25 Guo M,Song L P,Jiang Y,et al.Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1alpha independent mechanisms[J].Apoptosis,2006,11(1):67-77. 26 Pullarkat V,Sehgal A,Liang L,et al.Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors[J].Leuk Res,2012,36(8):966-973. 27 Roth M,Will B,Simkin G,et al.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation[J].Blood,2012,120(2):386-394. 28 Fukushima T,Kawabata H,Nakamura T,et al.Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia[J].Anticancer Res,2011,31(5):1741-1744. 29 Yamasaki T,Terai S,Sakaida I.Deferoxamine for advanced hepatocellular carcinoma[J].N Engl J Med,2011,365(6):576-578. 30 Kaloyannidis P,Yannaki E,Sakellari I,et al.The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival:a retrospective analysis[J].Transplantation,2010,89(4):472-479. 31 Michallet M,Sobh M,Morisset S,et al.Significant impact of iron chelation after allogeneic hematopoetic stem cell transplantation on disease recurrence:potential anti-leukemic activity[J].Blood,2013,122(21):180. 32 Greenberg PL,Attar E,Bennett JM,et al.NCCN clinical practice guidelines in oncology:myelodysplastic syndromes[J].J Natl Compr Canc Netw,2011,9(1):30-56. 33 Meynard D,Babitt JL,Lin HY.The liver:conductor of systemic iron balance[J].Blood,2013,123(2):168-176. 34 Oshrine B,Lehmann LE,Duncan CN.Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation[J].J Pediatr Hematol Oncol,2011,33(3):92-97. 35 Kikuchi S,Kobune M,Iyama S,et al.Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox[J].Free Radic Biol Med,2012,53(4):643-648. |